Spine Biologics Market Size - By Product [Bone Graft (Allograft, Autograft), Bone Graft Substitutes (Demineralized Bone Matrix, Synthetic Bone Graft), Platelet Rich Plasma], Surgery (ACDF, PLIF, TLIF), By End-use - Global Forecast to 2032
Published Date: August - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationSpine Biologics Market Size - By Product [Bone Graft (Allograft, Autograft), Bone Graft Substitutes (Demineralized Bone Matrix, Synthetic Bone Graft), Platelet Rich Plasma], Surgery (ACDF, PLIF, TLIF), By End-use - Global Forecast to 2032
Spine Biologics Market Size
Spine Biologics Market size in 2022 was valued at USD 2.2 billion in 2022 and is expected to witness CAGR of 4.3% by 2032 owing to increasing prevalence of spine deformities, growing awareness and patient preference for minimally invasive procedures, and technological advancements.
Spine biologics refer to a type of medical treatments or therapies that are developed by using biological materials or substances for treating various spinal conditions and disorders. They are used as alternatives to traditional surgical techniques, and provide biological support by promoting bone healing, fusion, and regeneration of the spine. They facilitate in reducing pain, improve functioning and better quality of life.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Spine Biologics Market Size in 2022 | USD 2.2 Billion |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 4.3% |
| 2032 Value Projection | USD 3.4 Billion |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 195 |
| Tables, Charts & Figures | 340 |
| Segments covered | Product, Surgery Type, End-user, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
COVID-19 Impact
The COVID-19 pandemic has shaken up the world of spine treatments. When the virus hit, lockdowns and travel bans were put in place. This meant that many planned surgeries, including spine surgeries, were put on hold or even canceled to keep people safe. As a result, far fewer spine surgeries were done, which meant that there was less demand for the special materials used in these surgeries. At the same time, the pandemic caused problems in the global supply chain, making it harder to produce and deliver these materials. Manufacturing plants had trouble keeping things running smoothly, which hurt production. This could lead to shortages or delays in getting the materials needed for spine surgeries.
With the vaccination efforts and infection control measures implemented to reduce the risk of infection, elective surgeries, including spine procedures. The backlog of postponed surgeries has created an increasing demand, leading to the recovery of the utilization of spine biologics. The pandemic has brought attention to the benefits of minimally invasive procedures, such as smaller incisions, fewer hospitalizations, and rapid recovery times. Spine biologics used in conjunction with minimally invasive techniques are expected to increase in demand due to the growing awareness and patient preference for such approaches.
Spine Biologics Market Driving Factors
As people get older, they're more likely to have back problems, such as slipped discs, narrowing of the spine, and broken bones due to osteoporosis. These conditions often need surgery, which may involve using special biological materials called "spine biologics." As more and more people live longer, there's been a surge in demand for spine surgeries and the use of spine biologics. Fortunately, surgical techniques and technologies have improved over time, making these surgeries safer and more effective for older patients. Spine biologics help speed up the healing process, improve surgical results, and reduce the risks associated with spine surgery in older adults.
Spine Biologics Market Analysis
Based on products, the spine biologics market is segmented into bone grafts, bone graft substitutes, platelet-rich plasma, bone marrow aspirate therapy, and other products. The bone graft segment is further sub-segmented into allografts and autografts. The bone graft substitute segment is further sub-segmented into demineralized bone matrix, synthetic bone grafts, and bone morphogenetic proteins. The bone graft substitutes segment accounted for the largest market share of 64.1% in 2022. In addition to this, it reduces the risk associated with the disease transmission, has osteoconductive properties, osteoinductive potential, and offers the structural integrity and stability.
Based on surgery type, the spine biologics market is classified into anterior cervical discectomy and fusion, posterior lumbar interbody fusion, transforaminal lumbar interbody fusion, anterior lumbar interbody fusion, lateral lumbar interbody fusion, and other surgery types. The anterior cervical discectomy and fusion segment was valued at USD 834.9 million in 2022. It is an effective treatment option for relieving pain caused by cervical disc disease. Most patients experience significant pain relief immediately after this surgery. They also help improve the functioning and movement of arms and hands.
The spine biologics market has different customers, like hospitals, surgical centers, and others. Among these, hospitals are expected to grow the fastest, at a rate of 4.1% per year until 2032. Hospitals have everything patients need for spine care, like specialized departments and teams that work together to offer a wide range of services. From figuring out what's wrong to surgery and aftercare, hospitals have it all. That's why they're a popular choice for people who need spine biologics. Hospitals also have agreements with insurance companies, which makes it easier for patients to get coverage and pay for these procedures. This makes it more convenient and affordable for patients to access these treatments.
Based on the region, North America spine biologics market is expected to reach USD 1.4 billion by 2032. The region has a relatively high prevalence of spinal conditions, such as degenerative disc disease, spinal stenosis, and spinal deformities. This results in a significant patient pool for surgical interventions, such as the use of spine biologics. In addition to this, North America has a well-developed healthcare system, presence of prominent players in this business, and increased awareness and demand for minimally invasive procedures.
Spine Biologics Market Share
The key players in the spine biologics market are
- Zimmer Biomet Holdings, Inc.
- Johnson and Johnson (Depuy Synthes)
- Orthofix Medical Inc.
- Stryker Corporation
- Arthrex, Inc.
- Medtronic, Inc.
- K2M, Inc.
- Exactech, Inc.
- Wright Medical Technology, Inc.
- Nuvasive, Inc.
Spine Biologics Industry News
- In February 2022, Orthofix Medical Inc. announced the market launch of Opus BA, a synthetic bioactive bone graft solution for cervical and lumbar spine fusion procedures. This helped company to boost the revenue and reach untapped markets.
- In April 2023, Bone Biologics received Human Research Ethics Committee approval to begin pilot clinical trial with NB1 bone graft in spinal fusion patients in Australia. It has significantly impacted the research and development of the product and also helped the company to expand their product portfolio.
The spine biologics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments
Click here to Buy Section of this Report
By Product
- Bone grafts
- Allografts
- Autografts
- Bone graft substitutes
- Demineralized bone matrix
- Synthetic bone grafts
- Bone morphogenetic proteins
- Platelet-rich plasma
- Bone marrow aspirate therapy
- Other products
By Surgery Type
- Anterior cervical discectomy and fusion (ACDF)
- Posterior lumbar interbody fusion (PLIF)
- Transforaminal lumbar interbody fusion (TLIF)
- Anterior lumbar interbody fusion (ALIF)
- Lateral lumbar interbody fusion (LLIF)
- Other surgery types
By End-user
- Hospital
- Ambulatory surgical centers
- Other end-users
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Switzerland
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of Middle East & Africa
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy